Day One Biopharmaceuticals Plunges 13.95% Despite Revenue Surge

On August 6, 2025, Day One experienced a significant drop of 13.95% in pre-market trading, reflecting a notable shift in investor sentiment.

Day One Biopharmaceuticals reported a substantial increase in net product revenue for its flagship product, OJEMDA, reaching $33.6 million in the second quarter of 2025. This marks a 10% increase from the previous quarter and a 310% rise from the same period last year. The company's strong financial performance was driven by the robust sales of OJEMDA, which exceeded 1,000 prescriptions in the second quarter.

The company's strategic focus on accelerating revenue growth with OJEMDA, advancing its pipeline, and expanding its portfolio has positioned it well for future success. Day One is progressing with its clinical trials, including the Phase 1a/b trial of DAY301 and the pivotal Phase 3 FIREFLY-2 trial, which is on track for enrollment completion in the first half of 2026.

Despite reporting a net loss of $30.3 million for the quarter, Day One significantly reduced its research and development expenses compared to the previous year. The appointment of industry leader Michael Vasconcelles, M.D., as Head of Research and Development, underscores the company's commitment to strengthening its R&D capabilities.

Looking ahead, Day One Biopharmaceuticals remains focused on delivering value to patients and shareholders through its strategic priorities, with a solid financial foundation and ongoing efforts to advance its clinical programs and expand its market presence. The company expects full-year revenue to be between $140 and $150 million, reflecting its confidence in continued growth and success.